6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶
生物活性靶点体外研究体内研究 用途与合成方法 MSDS 6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶价格(试剂级) 上下游产品信息
中文名称 | 6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶 |
---|---|
中文同义词 | 6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶;MTOR抑制剂(WAY-600;6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶|||WAY600;化合物WAY600;4-(6-(1H-吲哚-5-基)-1-(1-(吡啶-3-基甲基)哌啶-4-基)-1H-吡唑并[3,4-D]嘧啶-4-基)吗啉 |
英文名称 | WAY-600 |
英文同义词 | WAY-600;6-(1H-Indol-5-yl)-4-(4-morpholinyl)-1-[1-(3-pyridinylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidine;6-(1H-indol-5-yl)-4-morpholino-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine;WAY-600;WAY 600;4-[6-(1H-indol-5-yl)-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-4-yl]morpholine;1H-Pyrazolo[3,4-d]pyrimidine, 6-(1H-indol-5-yl)-4-(4-morpholinyl)-1-[1-(3-pyridinylmethyl)-4-piperidinyl]-;WAY-600 USP/EP/BP;4-(6-(1H-Indol-5-yl)-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine |
CAS号 | 1062159-35-6 |
分子式 | C28H30N8O |
分子量 | 494.59 |
EINECS号 | |
相关类别 | 细胞生物学试剂;小分子抑制剂,天然产物;Inhibitors;Akt;mTOR;PI3K;PI3K/Akt/mTOR |
Mol文件 | 1062159-35-6.mol |
结构式 |
6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶 性质
密度 | 1.43 |
---|---|
储存条件 | Store at -20°C |
溶解度 | 溶于 DMSO > 10 mM |
形态 | 粉末 |
酸度系数(pKa) | 16.08±0.30(Predicted) |
颜色 | 白色至米白色 |
6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶 用途与合成方法
生物活性
WAY-600 是有效,ATP 竞争型,选择性的 mTOR 抑制剂,抑制重组 mTOR 酶的 IC50 值为 9 nM。WAY-600 阻断 mTOR 复合物 1/2 (mTORC1/2) 组装和激活。
靶点
mTOR 9 nM (IC 50) | mTORC1
| mTORC2
| PI3K alpha 1.96 μM (IC 50) | PI3K gamma 8.45 μM (IC 50) |
体外研究
WAY-600 exhibits a concentration-dependent and time-dependent inhibition of f HepG2 and Huh-7 cells viability. Following WAY-600 (1-1000 nM) treatment, the number of HepG2 cell colonies is dramatically decreased. Meanwhile, BrdU incorporation in HepG2 cells is also inhibited with WAY-600 treatment. WAY-600 dose-dependently increases the activity of caspase-3 and caspase-9 in HepG2 cells. WAY-600 disrupts assemble of mTORC1 (mTOR-Raptor association) and mTORC2 (mTOR-Rictor association). Activation of mTORC1 (indicated by p-S6K1 and p-4E-BP1) and mTORC2 is almost blocked by WAY-600 (100 nM).
体内研究
Administration of WAY-600 (10 mg/kg, daily) inhibits HepG2 tumor growth in nude mice. Daily HepG2 tumor growth of WAY-600-administrated mice is significantly lower than that of vehicle control mice. Importantly, the in vivo anti-cancer activity by WAY-600 is further potentiated with the co-administration of MEK-162 (2.5 mg/kg, p.o. daily).
安全信息
MSDS信息
6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-15272 | 6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶 WAY-600 | 1062159-35-6 | 2mg | 1100元 |
2024/08/19 | HY-15272 | 6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶 WAY-600 | 1062159-35-6 | 5mg | 1900元 |